Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis

Ji Seon Kim, M.D.*, Seong Hae Jeong, M.D.*, Dae Hyun Kim, M.D., Jei Kim, M.D.

Department of Neurology, College of Medicine, Chungnam National University, Daejeon, Korea

Background and Purpose: The effect of low molecular weight heparin (LMWH) in the management of cerebral venous thrombosis (CVT) remains unclear. The present study was performed to determine the safety and feasibility of subcutaneous LMWH, with particular attention to hemorrhagic conversions.

Methods: LMWH (nadroparin, 7,500 IU, every 12 hours) was administered subcutaneously for 14 days to 12 patients diagnosed with CVT. Initial clinical manifestations, etiologies and the clinical courses after LMWH treatment were also evaluated. Possible hemorrhagic side effects, including aggravation of the initial hemorrhage and/or newly developed-hemorrhagic conversions were monitored by image analysis.

Results: Headaches and convulsive movements were frequent presenting symptoms for CVT. Clinical improvement was usually observed within 2 to 8 days after LMWH. Symptom stabilization was observed within 4 to 60 days. Neither clinical aggravations, nor newly developed parenchymal lesions were observed during LMWH maintenance. Associated parenchymal lesions were observed in 9 of the 12 patients, 5 of which manifested with hemorrhagic conversion, as detected by image analysis. However, no clinical and radiologic aggravation was noted in these 5 patients.

Conclusions: Our results suggest that LMWH may be safe and feasible in the management of CVT.

J Clin Neurol 1(2):134-141, 2005

Key Words: Cerebral venous sinus thrombosis, Low-molecular-weight heparin, Unfractionated heparin

INTRODUCTION

Clinical symptoms and signs of cerebral venous thrombosis (CVT) are extremely variable, and the diagnosis of CVT is thought to be under-recognized because of its nonspecific symptoms. In the early angiographic era, CVT had a high (30-50%) mortality. However, CVT related deaths have been reduced considerably (6.5-15%) with the advance of diagnostic tools such as computed tomography (CT) and magnetic resonance imaging (MRI), as well as early application of anticoagulants following diagnosis.

Unfractionated heparin has been the most common first-line drug for CVT, but its use has been the subject of much controversy because of reported hemorrhagic complications. The hemorrhagic conversion in the infarcted lesion is a major disincentive against the use of heparin. Low molecular weight heparin (LMWH) exerts an anticoagulant effect by inactivating factor Xa. LMWH also has a better antithrombotic-to-hemorrhagic ratio due to its low antithrombin effect. Perioperative
LMWH use has been shown to have no increase in bleeding risk during operation and post-operative drainage. Additionally, several studies have equated the efficacy of LMWH with that of unfractionated heparin in the management of deep vein thrombosis, venous thromboembolism, and unstable angina. Furthermore, LMWH has much better bioavailability, that is, a longer plasma half-life and less variable anti-coagulation effect with a fixed dose than unfractionated heparin.

The numerous publications reporting the benefits of LMWH, particularly the antithrombotic effects and better bioavailability, suggest that LMWH can replace unfractionated heparin in the early treatment of CVT. The present study evaluates whether LMWH is safe, feasible, and perhaps a better first-line drug for CVT.

### MATERIALS AND METHODS

1. **Diagnosis of CVT**

   CVT was diagnosed using pre- and post-enhanced T1-weighted MRI (T1WI), CT, magnetic resonance venography, and/or cerebral angiography. The imaging study was performed at the time of hospital admission for initial diagnosis of CVT. To evaluate temporal changes to brain lesions, each patient was subjected to follow-up MRI and/or CT studies at discharge. Both direct and indirect signs of thrombosis in the intracranial venous system were used for the diagnosis of CVT. Direct evidence of CVT included thrombi in the cerebral vein and sinuses on any imaging modality. Intensified venous collaterals, the presence of cork screw veins, broken bridging veins, venous dilatation, and delayed venous emptying were considered as indirect evidence for CVT. Combined parenchymal lesions with hemorrhagic conversion were also confirmed by density or signal changes on CT, T1WI, and/or gradient echo images. An increase in the initial hemorrhage size and/or newly developed bleeding detected follow-up imaging was categorized as an LMWH-related hemorrhagic complication.

2. **Causes of CVT**

   To evaluate the causes of CVT in patients, we assessed a history of risk factors that have been reported to be associated with CVT, such as oral contraceptive, parturition, infectious disease, ear disease, carcinoma, dehydration, marasmus, sepsis, acute lymphoblastic leukemia, chemotheraphy, systemic lupus erythematosus, Behçet's disease, osteoporosis, diabetes mellitus, homocystinuria, and iron deficiency anemia. Laboratory blood tests were also performed to determine the presence of coagulopathy, such as complete blood count (CBC), liver function test (LFT), prothrombin time (PT), activated partial thromboplastin time (aPTT), levels of protein C and S, antithrombin III, lupus anticoagulant, and anticardiolipin antibody. If the above historical and laboratory evaluation for CVT revealed no abnormality, we classified the case as not-determined etiology.

3. **Management and clinical courses of CVT**

   Twice daily subcutaneous injection of 7,500 IU nadroparin (Fraxiparine, Sanofi-Aventis, France) immediately followed the initial CVT diagnosis and was maintained for 2 weeks. For secondary prevention after the termination of the drug, oral anticoagulant (warfarin) or antiplatelet agent (aspirin) was prescribed depending on the individual risk factors.

   Initial manifestations were evaluated at CVT diagnosis and closely monitored for changes during nadroparin treatment until the initial neurological symptoms were normalized or stabilized. We recorded the onset of symptoms and/or signs prior to CVT diagnosis. We also recorded the interval from initial nadroparin treatment to initial evidence of clinical improvement. This interval time was used to estimate the drug's efficacy at managing CVT. Initial improvement was defined as the first signs of recovery from subjective symptoms observed at admission, such as headache or nausea, and/or objective neurological deficits, such as motor deficit, aphasia, and mental deterioration. Finally, the interval from initial nadropralin treatment to normalization or stabilization of initial neurological alterations was evaluated. Exacerbations of initial neurological deficits and/or newly
developed neurological deficits after treatment were classified as, “ineffective” or as, “side effect”.

**RESULTS**

1. Diagnosis of CVT

| Pt | Age/ Sex | Presenting Sx and Sn | Initial Assessment | Etiology | Start of therapy (days)* | Initial improvement (days)† | Normalization or stabilization of symptom (days)‡ | Aggravation of clinical symptoms |
|----|----------|----------------------|-------------------|----------|--------------------------|-----------------------------|----------------------------------|----------------------------------|
| 1  | 31/M     | HA, N/V              | HA                | ↓ protein C | 11 11 2 4             | -                           |                                  |                                  |
| 2  | 59/M     | Mental change        | Tumor metastasis (stomach cancer) | ND       | 3 2 2 30             | -                           |                                  |                                  |
| 3  | 26/F     | Convulsion, sensory aphasia | Sz                | ↓ protein S  | 16 1 20 30 | -                       |                                  |                                  |
| 4  | 31/F     | Convulsion           | Sz                | Postpartum  | 2 2 6 36             | -                           |                                  |                                  |
| 5  | 21/F     | HA, N/V              | HA                | COM, ↓ protein C and S, IDA | 30 2 8 60 | -                       |                                  |                                  |
| 6  | 53/F     | Convulsion, hemiparesis | Sz                | ND         | 1 1 2 11             | -                           |                                  |                                  |
| 7  | 51/F     | HA, hemianopia       | Brain tumor       | ND         | 17 14 2 15            | -                           |                                  |                                  |
| 8  | 25/F     | HA, convulsion       | Sz                | Oral contraceptive | 14 1 20 26 | -                       |                                  |                                  |
| 9  | 30/M     | HA, N/V              | Viral encephalitis | ↓ protein C, osteomyelitis | 16 10 2 222 | -                       |                                  |                                  |
| 10 | 76/M     | HA, Lt. hemiparesis, global aphasia | Lt MCA infarction | ↓ protein C, S | 9 1 3 12 | -                       |                                  |                                  |
| 11 | 27/M     | HA, fever            | Meningitis        | ↓ protein C, S, ↑ factor V | 16 14 3 50 | -                       |                                  |                                  |
| 12 | 45/F     | HA, convulsion       | Sz ds             | ↓ protein S, ↑ factor VIII | 3 1 2 2 | -                       |                                  |                                  |

Pt: patient number, Sx: symptom, Sn: sign, HA: headache, N/V: nausea/vomiting, Sz: seizure disorder, MCA: middle cerebral artery, ↓: deficiency of protein C or S, ↑: increased level of factor V and VIII, IDA: iron deficiency anemia, ND: not determined, COM: chronic otitis media, -: no aggravation of clinical symptoms, *interval from initial symptom to start of nadroparin, †interval from start of nadroparin to initial improvement of symptoms, ‡interval from start of nadroparin to normalization and/or stabilization of symptoms. **Table 1. Presenting manifestations, etiology, and clinical courses after LMWH start in CVT patients**
parenchymal lesions were distributed in variable hemispheric regions, including the temporal, parietal, and occipital lobes. In patients 2 and 12, venous infarctions in deep structures, such as basal ganglia, thalami, and/or the centrum semiovale, were associated with the venous thrombi located in inferior cerebral veins (Table 2).

2. Causes of CVT

Common risk factors responsible for CVT were found in all but two patients (cases 6 and 7) (Table 1). Protein C and/or S deficiency were determined to be the most frequent cause, affecting 7 out of 12 patients. Deficiencies of both proteins were detected in three patients. Two patients had not only protein S and/or C deficiency, but also elevated levels of blood factor V (case 11) and blood factor VIII (case 12). Postpartum and oral contraceptives were checked in cases 4 and 8, respectively. Additionally, chronic otitis media in case 5 and osteomyelitis in the left lower tibia in case 9 were associated with protein C and/or S deficiency. Iron deficiency anemia (Hb=7.3 gm/dl) was detected in case 5. Case 2 had been diagnosed with stomach cancer 6 months previously but had no abnormality on the evaluated history and laboratory work-up. In all patients, warfarin was maintained at levels 2 to 3 of the international normal range of prothrombine time for secondary prevention of CVT.

3. Clinical manifestations and courses of CVT

Headache was the most frequent presenting symptom, and associated with neurological deficits, such as convulsive movement, sensory or global aphasia, hemiparesis, and hemianopsia. However, convulsive movement was the dominant manifestation without the headache symptoms in three patients. A mental status of deep drowsiness was the presenting manifestation in case 2. Interestingly, before the availability of imaging diagnosis for CVT, the likely presumptive diagnosis for case 2 was a seizure disorder. Other patients were initially determined as having variable diagnoses, with headaches in two patients, metastasis of stomach cancer, brain tumor, encephalitis, cerebral infarction, and meningitis (Table 1).

CVT was diagnosed rapidly (within 1 to 3 days) when the patients showed characteristic neurological

Table 2. Radiological findings on initial and follow-up brain imaging

| Pt | Thrombus in sinus | Parenchymal lesion | Hemorrhage on initial image | Follow-up parenchymal lesion |
|----|-------------------|--------------------|-----------------------------|-----------------------------|
| 1  | SSS, ISS, TS      | No                 | No                          | -                           |
| 2  | ICV, STS          | Both BG, thalamus  | No                          | +                           |
| 3  | Lt. TS            | Lt. temporal       | Yes                         | -                           |
| 4  | Lt. TS            | Lt. frontal, Rt parietal | No          | +                           |
| 5  | Lt. TS, SMS       | No                 | No                          | -                           |
| 6  | SSS Lt. TS        | Both parietal      | No                          | -                           |
| 7  | Rt. TS            | Lt. parieto-occipital | Yes                     | +                           |
| 8  | SSS               | Rt. Parietal       | Yes                         | +                           |
| 9  | SSS STS, both TS  | Lt. parietal, Rt parietal | Yes*                   | +                           |
| 10 | Lt. cortical vein | Lt. fronto-parietal | Yes                        | +                           |
| 11 | SSS, SMS, Rt. TS, DS | No                 | No                          | -                           |
| 12 | ICV, ISS          | Both BG, thalamus, centrum semiovale | No       | -                           |

Pt: patient number, Lt.: left, Rt.: right, SSS: superior sagittal sinus, ICV: inferior cerebral vein, ISS: inferior sagittal sinus, TS: transverse sinus, SMS: sigmoid sinus, DS: dural sinus, BG: basal ganglia, frontal: frontal lobe, parietal: parietal lobe, occipital: occipital lobe, *hemorrhagic conversion after starting heparin, -: no remaining encephalomalatic change on follow-up image, +: remaining encephalomalatic change on follow-up image.
deterioration at the hospital. However, the diagnosis was usually delayed (11 to 30 days from the initial onset of symptoms), when the patient first suffered from non-specific neurological manifestations, such as headache and nausea. Improvement of the initial symptoms was usually detected within 2 to 8 days after taking nadroparine, irrespective of a delay in the diagnosis of CVT. In two patients (case 3 and 8), improvement was detected after 20 days of nadroparine because clinical evaluations were impossible due to the inability to communicate. One patient showed sensory aphasia at admission, while another patient presented with a deep drowsiness during the management with nadroparine. Normalization to the previous neurological condition occurred rapidly in two patients, within 2 and 4 days in cases 1 and 12, respectively. Most patients normalized their initial neurological state within 11 to 60 days. Patient 9, who had marked thrombi and hemorrhagic conversion in both cerebral cortices, showed stabilization of right side hemiplegia by 222 days of nadroparine treatment, improving to Grade III.

4. Safety of LMWH for hemorrhagic-converted venous infarction

Hemorrhagic conversion was detected in five of the nine patients with venous infarctions: cases 3, 7, 8, 9, and 10. In case 9, severe thrombi in the superior sagittal sinus, inferior sagittal sinus, and sigmoid sinus (Fig. 1-B) and parenchymal lesion without hemorrhagic conversion were detected in the initial imaging study (Fig. 1-A). Unfractionated heparin was administered immediately following the CVT diagnosis, and 2 days later the mental state had decreased from alert to deep drowsiness. Motor weakness on the right extremities had also aggravated to hemiplegia. On the follow-up brain CT study, hemorrhagic conversion had developed in the previous infarcted lesions (Fig. 1-C). The mental state markedly improved 2 days after replacing heparin with nadroparin and no aggravation of clinical symptoms was detected during the maintenance with nadroparin.

Associated hemorrhage was observed in the initial brain image of four patients. Again, nadroparine did not cause clinical or radiological aggravation. In case 3, a marked temporal lobe hemorrhagic infarction was observed on the initial CT, (Fig. 2-A) and the left lateral sinus was evident in cerebral venography performed at admission. (Fig. 2-B) The initiation of nadroparine treatment resulted in no aggravation of mental status, even though the surrounding edema increased in the follow-up study (Fig. 2-C). The patient recovered to an alert and cooperative status without neurological findings after termination of the nadroparine schedule. Encephalomalatic change at the hemorrhagic converted parenchymal lesion remained in case 9 (Fig. 1-D) and 4. (Fig. 2-D) Convulsive movement developed after hospital discharge in both of these patients, and an anti-epileptic drug was prescribed to prevent recurrence. Hemorrhagic-converted cerebral lesions were observed in the initial imaging study in three other patients. These patients showed clinical improvement after taking nadroparine, and no aggravation of the initial manifestations as well as radiological problems were observed. However, hemorrhagic converted lesions remained as encephalomalatic

Figure 1. Case 9. Heparin-induced hemorrhagic conversion on initial and follow-up images. (A) Absence of parenchymal lesion on an initial CT scan, (B) marked thrombi in superior sagittal and straight sinus on initial enhanced T1WI, (C) hemorrhagic conversion on a follow-up non-enhanced CT scan after 2 days of heparin treatment, and (D) remaining encephalomalatic lesion on hemorrhagic converted lesion on a follow-up non-enhanced CT scan 2 months into treatment.
The patients included in the present study showed improvement after taking LMWH without clinical aggravation suggesting its general superiority over unfractionated heparin at managing CVT. Unfractionated heparin had been the preferred choice for anticoagulation of CVT, with many series demonstrating good clinical prognosis.\(^3,15,16\) Recently, however, LMWH has been widely speculated as an alternative for managing and preventing venous thromboembolism with equal effectiveness.\(^17-20\)

Although unfractionated heparin may prevent the progression of thrombosis and further infarction, it required very careful administration because of its hemorrhagic side effects.\(^5,6\) A previous randomized trial has shown that unfractionated heparin was both safe and effective at managing CVT.\(^3\) However, the results had been debated due to the small sample size, questionable outcome criteria, and a long treatment delay.\(^21,22\) In the present study, we also experienced clinical aggravation after initial heparin treatment in case 9, and newly developed hemorrhagic conversion was confirmed in the follow-up imaging study. Therefore, unfractionated heparin should be used with caution as a first-line drug for CVT patients.

LMWH presents a lower risk of bleeding than unfractionated heparin in the management of venous thromboembolism.\(^10\) The probability of bleeding is not increased during the perioperative period of major surgeries when LMWH was used.\(^8,9\) Therefore, LMWH would be expected to be a safe anticoagulant for managing CVT, especially for treating hemorrhage-converted venous infarctions. A previous randomized trial determined that LMWH was sufficiently safe for managing hemorrhagic converted CVT.\(^20\) CVT patients included in the present study showed no evidence of LMWH-associated hemorrhage. Even if they present hemorrhagic conversion in the initial imaging studies, the initial manifestations improved rapidly after LMWH was administered without clinical or radiological aggravations. Patient 9 exhibited heparin-induced clinical and radiological aggravations, but the clinical manifestations rapidly stabilized after an anticoagulation switch to LMWH. Therefore, the present study provides further supports for the safety of LMWH in managing CVT and venous thromboembolism.

Unfractionated heparin presents other practical limitations, such as a narrow window of therapeutic time, less predictable kinetics, platelet activation, and the inability to inhibit clot-bound thrombin.\(^23\) Consequently, unfractionated heparin requires frequent laboratory monitoring and close observation to prevent heparin-induced complications.\(^24\) On the other hand, LMWH has better bioavailability, limited non-specific binding, and non-dose-dependent half-life, as well as the ease of subcutaneous injections without laboratory monitoring.\(^7\) In several other studies, LMWH performed similarly, if not better, at preventing and managing both venous thromboembolism and CVT.\(^17-20\) Furthermore, the convenient
subcutaneous injection without laboratory monitoring makes LMWH a better first-line CVT drug than unfractionated heparin.25,26

The ideal LMWH regimen for CVT has not yet been established, even though its efficacy and safety have been widely reported for venous thromboembolism and CVT. Long-term LMWH treatments (up to 3 months) are reportedly effective at managing symptomatic venous thromboembolism.27 Other studies have shown that short term LMWH treatments (5 to 7 days) was effective at treating thromboprophylaxis.28,29 Two weeks of LMWH maintenance was recently recommended for the prevention of venous thromboembolism.19 For CVT, however, LMWH was administered twice a day for 3 weeks in a randomized trial.20 In the present study, administration of LMWH twice a day for 2 weeks produced clinically acceptable results. Therefore, 2 weeks might be sufficient for CVT or thromboembolism management, although additional trials are required to verify the appropriate daily dosage and duration of LMWH maintenance.

In conclusion, LMWH was found to be safe and effective for managing CVT. The small number of tested patients and the lack of a control group receiving unfractionated heparin limit the applicability of our data. However, the rapid improvements without clinical or radiological aggravations strongly support previous studies showing the safety and efficacy associated with LMWH, and hence its potential as a better first-line agent for treating hemorrhagic converted CVT patients.

REFERENCES

1. Perkin GD. Cerebral venous thrombosis: developments in imaging and treatment. J Neurol Neurosurg Psychiatry 1995;59:1-3.
2. Bousser M-G, Barnett BJM. Cerebral venous thrombosis. In: Mohr JP, Choi DW, Grotta JC, Weir B; Wolf AP. Stroke. Pathophysiology, Diagnosis, and Management, 3rd ed. Philadelphia: Churchill Livingstone, 2004;301-325.
3. Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellekof M et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600.
4. Stam J, de Bruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis. Stroke 2003;34:1054-1055.
5. DiNubile MJ. Septic thrombosis of the cavernous sinuses. Arch Neurol 1988;45:567-572.
6. Feldenzer JA, Bueche MJ, Venes JL, Gebarski SS. Superior sagittal sinus thrombosis with infarction in sickle cell trait. Stroke 1987;18:656-660.
7. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
8. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg. 1995;82:496-501.
9. Torholm C, Broeng L, Jorgensen PS, Bjerregaard P, Josephsen L, Jorgensen PK et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br 1991;73:434-438.
10. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607.
11. Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 2005;3:473-481.
12. SYNERGY Executive Committee. Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa inhibitors. The SYNERGY trial: study design and rationale. Am Heart J 2002;143:952-960.
13. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292;55-64.
14. Biller J, Love BB. Vascular disease of the venous system. In: Bradley WG, Daroff RB, Fenichel GH, Jankovic J. Neurology in Clinical Practice, 4th ed. Philadelphia: Elsevier Inc., 2005:1243-1245.
15. Brucker AB, Vollert-Rogenhofer H, Wagner M, Stiegblauer K, Felber S, Trenkler J et al. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis 1998;8:331-337.
16. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992;10:87-111.
17. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary
18. Siragusa S, Cosni B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. *Am J Med* 1996;100:269-277.

19. Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. *Circulation* 2004;110:IV13-IV19.

20. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low molecular-weight heparin for cerebral sinus thrombosis. *Stroke* 1999;30:484-488.

21. Stam J, Lensing AW, Vermeulen M, Tijssen JG. Heparin treatment for cerebral venous and sinus thrombosis. *Lancet* 1991;338:1154.

22. Enevoldson TP, Russell RWR. Heparin treatment in sinus venous thrombosis. *Lancet* 1991;338:1153-1154.

23. Das P, Moliterno DJ. Fractionating heparins and their clinical trial data--something for everyone. *JAMA* 2004;292:101-103.

24. Hirsh J. Heparin. *N Engl J Med* 1991;324:1565-1574.

25. van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. *TASMAN Study Group. Thromb Haemost* 1998;79:259-263.

26. Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. *CMAJ* 1998;159:931-938.

27. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. *J Thromb Haemost* 2003;1:1906-1913.

28. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). *Thromb Haemost* 1989;62:1046-1049.

29. Lindmarker P, Holmstrom M, Granqvist S, Johnson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost* 1994;72:186-190.